While everyone debates cultivation, brands and legalisation, something quite different is happening behind the scenes:
👉 Investors are no longer buying cannabis companies. 👉 They are buying data.
And that's uncomfortable. Because it means:
Your greenhouse is not an asset, and your brand is interchangeable.
But:
📊 Your data is not.
Why are so many deals happening right now anyway – despite regulatory uncertainty?
Because the market has long since decided: +3,300% more prescriptions since 2024.
- The patient is there.
- The demand is real.
- The rest is just structure.
🧠 What buyers really want in 2026:
1️⃣ Data > Production
Whoever knows what doctors prescribe and what patients need controls the market.
Not the one who grows.
2️⃣ Access > Marketing
Pharmacies & doctors are the real gatekeepers.
No ads.
No brands.
Just trust.
3️⃣ Asset-light > Capital-intensive
The highest valuations go to companies that:
- have no production
- but connect everything
➡️ Patient
➡️ Doctor
➡️ Pharmacy
➡️ Product
💥 Hard truth:
Many cannabis companies don't get bought.
Because they have nothing anyone wants to integrate.
🌍 And now even more pressure is coming:
US Schedule III will unlock capital. -> More buyers. -> More competition.
➡️ And less patience for weak business models.
🚀 Conclusion:
The market is shifting away from "cannabis"
towards data, access and infrastructure.
💬 An honest question:
If a buyer turns up tomorrow – will they buy your product… or your data?